AVIGI Therapeutics

Meet our founder and CEO Vincent Lit, PhD at BIO2025, June 16-19 in Boston! #BIO2025 https://lnkd.in/emWPWiZv

Announcing our Scientific Advisory team Prof. Hermen Overkleeft  A global expert in glycosidase chemical biology, Prof. Overkleeft’s pioneering work has led to the founding of Azafaros, a clinical-stage biotech company. His ability to translate fundamental research into therapeutic candidates will be instrumental in shaping AVIGI’s drug discovery strategy. Prof. Gideon Davies  Prof. Davies is widely respected for his work on carbohydrate-active enzymes and mechanistic enzymology. His structural and functional studies of glycosyltransferases and hydrolases have broad implications in human health and disease, offering a critical foundation for AVIGI’s enzyme-targeting platform. Dr. Liang Wu  Dr. Wu has played a key role in elucidating the structure and function of human heparanase, AVIGI’s lead target. His structural insights have directly informed the design of AVIGI’s lead compound, enabling a transition from hypothesis-driven exploration to precision engineering. https://lnkd.in/e99wSEwV

Announcing our Scientific Advisory team Prof. Hermen Overkleeft  A global expert in glycosidase chemical biology, Prof. Overkleeft’s pioneering work has led to the founding of Azafaros, a clinical-stage biotech company. His ability to translate fundamental research into therapeutic candidates will be instrumental in shaping AVIGI’s drug discovery strategy. Prof. Gideon Davies  Prof. Davies is widely respected for his work on carbohydrate-active enzymes and mechanistic enzymology. His structural and functional studies of glycosyltransferases and hydrolases have broad implications in human health and disease, offering a critical foundation for AVIGI’s enzyme-targeting platform. Dr. Liang Wu  Dr. Wu has played a key role in elucidating the structure and function of human heparanase, AVIGI’s lead target. His structural insights have directly informed the design of AVIGI’s lead compound, enabling a transition from hypothesis-driven exploration to precision engineering. https://lnkd.in/e99wSEwV

We are excited to have been selected to join the European Hi-Tech Delegation Tour to China. https://lnkd.in/eC9rx7Cs

We're thrilled to announce Dr. Alessandro Noseda as our Medical Advisor. Read more: https://lnkd.in/dmF8Tvc6

We're seeking a Science and Business Intern to join us for a minimum of 6 months. This position offers a unique blend of scientific research understanding and business development acumen at an early stage in our companies growth. For more information see our website: https://lnkd.in/eHyzWP5p

Firsts hold a special place in our hearts, the inaugural taste of what becomes a favorite dish, that unforgettable first kiss, you understand the significance. This principle extends perfectly to a startup's first investment, and we're thrilled to announce that AVIGI Therapeutics has reached this pivotal milestone with UNIIQ. This €350k investment transcends mere financial support. While the capital certainly empowers our continued development efforts, what resonates equally is the powerful vote of confidence it represents. Our first investor is effectively the first to declare: "We believe in your vision and your innovation!" This validation matters tremendously to our team and to everyone who has contributed to bringing this project to its current stage. The journey here wasn't brief, it encompassed five years of rigorous academic development across multiple research groups to create technology worthy of patent protection, followed by two additional years and two grants to prepare our concept for successful commercialization. As with all meaningful firsts, symbolism plays a role. UNIIQ's tradition of presenting engraved stones with each investment beautifully represents the foundation stone of a new enterprise. We extend our heartfelt gratitude to UNIIQ - Finance for the Future and Libertatis Ergo Holding B.V. for being our first believers and providing this critical stepping stone for our future growth. With this foundation in place, the sky is the limit. https://www.avigitx.com/

Join our team as a Cancer Biology PhD to advance our first-in-class heparanase inhibitor program. Lead preclinical studies and develop translational strategies for our breakthrough cancer therapy. https://lnkd.in/e-dmk3Dx

Telling a story is hard but evertime you do it you get better. Today we told our story at the Academic Startup Competition At AVIGI we’re on a mission to make advanced solid tumors treatable again by targeting cancers cascades that make these tumors so hard to treat Although we didn’t win, we’re still grateful for the opportunity to present alobgside the Netherlands finest academic startup companies. The quality of the competing life science companies was incredible and we want to congratulate the many companies that showcased themselves. Our journey continues and we remain dedicated to developing this treatment so that it reaches patients with untreatable tumors.